Month: June 2024

CHICAGO, June 18, 2024 (GLOBE NEWSWIRE) — GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced the company will present at the Noble Capital Markets Consumer, Communications, Media, and Technology Emerging Growth Virtual Equity Conference on Wednesday, June 26, 2024, at 2:00 p.m. Eastern Time. A live webcast of the presentation may be accessed through a link that will be posted on GoHealth’s Investor Relations website, https://investors.gohealth.com/. A replay will be available through the same link following the conference. About GoHealth, Inc. GoHealth is a leading health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they...

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. About CytomX TherapeuticsCytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed...

– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator (CAM) candidate in development for the treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV (cHBV) infection is a leading cause of chronic liver disease and liver transplants globally, with the World Health Organization estimating that over one million people died in 2022 from HBV-related causes. Current...

– First Patient Dosed in Expanded Access Program and Enrollment Ongoing – IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has initiated an Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP and enrollment in the study is ongoing. “Bladder cancer is a highly recurrent disease with few treatment options available to patients,” said Ambaw Bellete, President &...

MALVERN, Pa., June 18, 2024 (GLOBE NEWSWIRE) — via IBN — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), is pleased to announce that it has been selected to present the data from its latest Alzheimer’s study in an extended 45-minute session at the Alzheimer’s Association International Conference® 2024 (AAIC®). The conference will take place from July 28 to August 1 in Philadelphia, USA, and online. Dr. Cheng Fang, Senior VP of Research & Development at Annovis Bio, along with Kathleen A. Welsh-Bohmer, Ph.D., Professor in Psychiatry and Neurology at Duke University, and Maria L. Maccecchini, Ph.D., Founder, President, CEO of Annovis Bio Inc., will deliver a 45-minute...

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA® (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our research team believes that this study is an important contribution to the economic evaluation of sotagliflozin, a novel SGLT inhibitor, from the perspective of the U.S. healthcare system. Our results demonstrated that in people...

SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here. The event will feature Rahul Aggarwal, M.D. (University of California San Francisco), who will discuss the unmet need and evolving treatment landscape for prostate cancer, as well as the clinical development program for FG-3246* (also known as FOR46), a CD46 targeting antibody-drug conjugate (ADC) with first-in-class potential for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The initiation of a Phase 2 monotherapy trial in mCRPC is expected in the second half of 2024. The event will additionally review data from the Phase 1b/2 study evaluating FG-3246 in combination with...

Expands reach of authID’s next-gen biometric identity platform with integration to Syntrove’s risk and fraud technology platform Denver, June 18, 2024 (GLOBE NEWSWIRE) — authID Inc. [Nasdaq: AUID], a leading provider of innovative biometric identity verification and authentication solutions, and Syntrove, a leading consulting and professional services firm specializing in providing risk, data, delivery and technology expertise, today announced they have signed an OEM agreement that will integrate authID’s biometric capabilities in fighting malicious, generative AI-driven fraud, deepfakes, and cyberattacks into the Syntrove offering. Syntrove, whose vision is to be at the forefront of technological and process evolution, will now distribute authID’s next-gen authentication solutions to its portfolio of leading banking, insurance,...

With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare system Through a share purchase agreement Grifols has sold a 20% equity stake in SRAAS to Haier Group for RMB 12.5 billion (approximately EUR 1.6 billion) Grifols and SRAAS extend their exclusive albumin distribution agreement over the next 10 years, and SRAAS has the option to prolong it through 2044 Grifols will use all proceeds to comply with its commitment to deleverageBARCELONA, Spain, June 18, 2024 (GLOBE NEWSWIRE) — Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group...

Launch of Yield-Bearing Bitcoin (BTC) ETP on Börse Frankfurt: Valour Inc. and Core Foundation collaborate to introduce the world’s first yield-bearing Bitcoin (“BTC”) ETP on the Börse Frankfurt Exchange, previously launched on the Nordic Growth Market (“NGM”) with a 1.9% management fee, offering German investors exposure to Bitcoin with a 5.65% yield.Powering Valour Bitcoin Staking (BTC) EUR ETP with Core Blockchain: The Core blockchain network, powered by Bitcoin, forms the foundation for Valour Bitcoin Staking (BTC) EUR ETP (ISIN: CH1213604544), providing Ethereum Virtual Machine (“EVM”) compatibility and the innovative Satoshi Plus consensus mechanism to enhance security and scalability.Simplified Investment with Valour Bitcoin Staking (BTC) EUR ETP: Valour Bitcoin Staking (BTC) EUR ETP streamlines Bitcoin investment by delegating...